ALK and adenocarcinoma: Twenty two patients had adenocarcinomas (18 of whom had no sensitizing mutations and 3 with unknown EGFR/ALK status), 19 had squamous cell carcinomas, in 1 patient it was not possible to further differentiate the tumour beyond determining that it was a NSCLC.1 patient had no definitive invasive malignancy demonstrated on biopsy but was treated due to high clinical suspicion.